660 — Wai Chun Bio Technology Income Statement
0.000.00%
Last trade - 00:00
- HK$17.15m
- HK$200.22m
- HK$773.65m
- 28
- 97
- 11
- 40
2018 December 31st | 2019 December 31st | 2020 December 31st | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 18 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 481 | 579 | 568 | 1,007 | 774 |
Cost of Revenue | |||||
Gross Profit | 15.5 | 49 | 48.9 | 90.2 | 50.4 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 528 | 564 | 558 | 982 | 762 |
Operating Profit | -46.9 | 15.1 | 9.53 | 24.7 | 11.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -53 | 9.06 | 1.61 | 3.78 | -5.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -53.2 | 8.99 | 0.995 | -1.39 | -10.1 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -53.6 | -3.16 | -8.15 | -21.5 | -15.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -53.6 | -3.16 | -8.15 | -21.5 | -15.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.322 | -0.019 | -0.05 | -0.096 | -0.091 |
Dividends per Share | |||||
Special Dividends per Share |